Filing Flows › Heron Therapeutics (HRTX) › Aponvie revenue
Heron Therapeutics (HRTX) Aponvie revenue by quarter
Heron Therapeutics' Aponvie revenue was $4.3M in Q2 2026 (second quarter 2026), +26% from Q1 2026. Over the last 7 quarters it ranged from $1.9M (Q4 2024) to $4.3M (Q2 2026).
| Quarter | Aponvie revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $4.3M | +26% | +74% |
| Q1 2026 | $3.4M | -11% | +50% |
| Q4 2025 | $3.8M | +26% | +97% |
| Q3 2025 | $3.0M | +23% | — |
| Q2 2025 | $2.5M | +9% | — |
| Q1 2025 | $2.3M | +17% | — |
| Q4 2024 | $1.9M | — | — |
Q2 2026 at a glance
Heron Therapeutics, Q2 2026: revenue $37.7M (+1% year over year), operating margin -5.4%, net loss $5.5M, operating cash flow −$2.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Heron Therapeutics' Aponvie revenue?
Heron Therapeutics' Aponvie revenue was $4.3M in Q2 2026 (second quarter 2026), +26% from Q1 2026.
How has Heron Therapeutics' Aponvie revenue changed?
Over the last 7 quarters it ranged from $1.9M (Q4 2024) to $4.3M (Q2 2026).